Open an account

Annexon

ANNX · NASDAQ

$3.83−$0.18 (−4.49%)TodayMarket closed ·
Prev close $4.01

About ANNX

Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. The company is headquartered in Brisbane California, California and currently employs 96 full-time employees. The company went IPO on 2020-07-24. The company identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology, using its proprietary platform. Its lead candidate, ANX005, an investigational, full-length monoclonal antibody (mAb), is formulated for intravenous administration as the potential first targeted treatment for patients with Guillain-Barre Syndrome (GBS). The company is advancing ANX1502, a novel small-molecule inhibitor of classical complement designed for oral administration in a range of chronic autoimmune diseases. The company is also advancing ANX007, designed to block C1q locally in the eye, to provide complete protection against excess classical complement activity and the loss of photoreceptor neurons.

Employees
96
Headquarters
Brisbane California, California
Listed
Jul 24, 2020
Sector
Health Care
Industry
Biotechnology
Website
annexonbio.com

ANNX key statistics

Market cap
760.21M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
3.40M
Volume
5.62M
Open price
$4.02
High today
$4.06
Low today
$3.78
52 Week high
$7.18
52 Week low
$2.54

Annexon (ANNX) at a glance

Annexon (ANNX) last traded at $3.83, with a market cap of 760.21M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $3.78 and $4.06. The current price is 1.3% above the day's low and 5.6% below its high.

Volume so far is 5.62M shares, above the average of 3.40M shares a day.

Over the past year Annexon has ranged from $2.54 to $7.18, and now sits 28% of the way up that range.

Annexon met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.28 per share against an estimate of -$0.2438.

The average analyst price target is $16.03, 318.5% above the current price, from 8 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

75%of 8 analyst ratings say Buy
  • Buy75.0%
  • Hold25.0%
  • Sell0.0%
Price target · 10 analystsAvg $16.03
Low
$7.07
Now
$3.83
High
$28.35

ANNX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 12.1% on average.

  1. Q3 FY24: reported -$0.25 per share against an estimate of -$0.2639
  2. Q4 FY24: reported -$0.33 per share against an estimate of -$0.2746
  3. Q1 FY25: reported -$0.37 per share against an estimate of -$0.3023
  4. Q2 FY25: reported -$0.34 per share against an estimate of -$0.373
  5. Q3 FY25: reported -$0.37 per share against an estimate of -$0.3468
  6. Q4 FY25: reported -$0.28 per share against an estimate of -$0.319
  7. Q1 FY26: reported -$0.23 per share against an estimate of -$0.2949
  8. Q2 FY26: reported -$0.28 per share against an estimate of -$0.2438

ANNX news

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • 12 Health Care Stocks Moving In Friday's After-Market Session

  • Avi Kapoor

    Stanley Black & Decker To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday

  • Vandana Singh

    Annexon's Investigational Drug Shows Rapid Recovery And Durable Benefit In Rare Neurological Disorder

  • Press releaseBusiness Wire

    Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors

  • Press releaseGlobe Newswire

    Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones

  • Press releaseGlobe Newswire

    Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year

  • Press releaseGlobe Newswire

    Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones

Similar companies

Companies in the same industry as Annexon

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.